Drug-Eluting stents reduce risk of thrombosis

Drug-Eluting stents reduce risk of thrombosis
Cobalt-chromium everolimus eluting stents are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting stents, according to a meta-analysis published online March 23 in The Lancet.

(HealthDay) -- Cobalt-chromium everolimus eluting stents (CoCr-EES) are associated with a significantly lower rate of stent thrombosis within two years of implantation, compared with other bare-metal and drug-eluting stents, according to a meta-analysis published online March 23 in The Lancet.

Tullio Palmerini, M.D., from the Policlinico S. Orsola in Bologna, Italy, and colleagues compared the risk of between bare-metal and drug-eluting stents in an analysis of 49 trials involving 50,844 patients.

The researchers found that, compared with bare-metal stents, the one-year definite stent thrombosis rate was significantly lower with CoCr-EES (odds ratio [OR], 0.23). This difference was seen as early as 30 days (OR, 0.21) and continued to be significant from 31 days to one year (OR, 0.27). Compared with paclitaxel-eluting stents, permanent polymer-based sirolimus-eluting stents, phosphorylcholine-based zotarolimus-eluting stents, and Resolute zotarolimus-eluting stents, CoCr-EES were associated with significantly lower rates of one-year definite stenosis (ORs, 0.28, 0.41, 0.21, and 0.14, respectively). CoCr-EES correlated with significantly lower rates of definite stent thrombosis compared with bare-metal and paclitaxel-eluting stents after two years of follow-up (OR, 0.35 and 0.34, respectively). At two-year follow-up, no other drug-eluting stent had lower definite thrombosis rates compared with bare-metal stents.

"In randomized studies completed to date, CoCr-EES has the lowest rate of stent thrombosis within two years of implantation. The finding that CoCr-EES also reduced stent thrombosis compared with bare-metal stents, if confirmed in future , represents a paradigm shift," the authors write.

Several authors disclosed to the pharmaceutical, medical device, and biotechnology industries.


Explore further

Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Citation: Drug-Eluting stents reduce risk of thrombosis (2012, March 23) retrieved 26 October 2021 from https://medicalxpress.com/news/2012-03-drug-eluting-stents-thrombosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors